Types of Sulfonylureas
Sulfonylureas are divided into first-generation agents (tolbutamide, chlorpropamide, tolazamide) and second-generation agents (glyburide, glipizide, glimepiride, gliclazide), with second-generation drugs being more potent and having fewer drug interactions, making them the preferred choice for clinical use 1, 2.
First-Generation Sulfonylureas
The first-generation agents are less potent and require higher doses:
- Tolbutamide: The weakest sulfonylurea, making it potentially suitable for initiating therapy in elderly patients, though rarely used today 2
- Chlorpropamide: Has a long duration of action and increased incidence of side effects, making it less popular in modern practice 2
- Tolazamide: Less expensive but less powerful than second-generation agents 3
These agents have numerous drug interactions and are largely obsolete in contemporary diabetes management 2.
Second-Generation Sulfonylureas
Second-generation agents are more potent, allowing for lower doses and once or twice-daily dosing:
Glyburide (glibenclamide): Generally not recommended in chronic kidney disease due to hypoglycemia risk 1. May produce greater incidence of hypoglycemia, particularly in elderly patients or those with significant renal impairment 2
Glipizide: Should be initiated conservatively in CKD to avoid hypoglycemia 1. Requires twice-daily dosing compared to glyburide's once-daily schedule 2
Glimepiride: Initiate conservatively in CKD to avoid hypoglycemia 1. Has been shown to be cardiovascular safe, addressing the FDA special warning on increased CV mortality based on older sulfonylurea studies 1
Gliclazide (modified release): Provides good 24-hour glycemic efficacy with less frequent hypoglycemic events than other sulfonylureas, and has antioxidant and anti-inflammatory properties 4
Typical Adult Dosing Considerations
While specific dosing varies by agent and should follow manufacturer prescribing information 1, key principles include:
- Renal function assessment is critical: Glyburide should be avoided in CKD, while glipizide and glimepiride require conservative initiation 1
- Lower doses are needed as kidney function declines to prevent hypoglycemia
- Second-generation agents allow once or twice-daily dosing schedules
Clinical Considerations for Use
Use sulfonylureas with extreme caution in patients at risk for hypoglycemia, particularly when combined with insulin 1. The 2025 ADA guidelines classify second-generation sulfonylureas as having:
- High glucose-lowering efficacy
- Yes to hypoglycemia risk
- Weight gain as a side effect
- Unknown cardiovascular benefit (though glimepiride specifically shown to be CV safe) 1
Common Pitfalls to Avoid
- Do not use glyburide in CKD patients - highest hypoglycemia risk in this population 1
- Avoid in combination with insulin without careful monitoring - significantly increases hypoglycemia risk 1
- Be aware of the FDA warning on CV mortality - based on older agent tolbutamide, though glimepiride has been shown safe 1
- Recognize declining role in modern therapy - newer agents (SGLT2 inhibitors, GLP-1 RAs) are now preferred for organ protection and cardiovascular/renal benefits 5, 6
Current Position in Treatment Algorithm
The 2025 ADA/EASD consensus advocates for earlier use of SGLT2 inhibitors and GLP-1-based therapies, potentially from diagnosis, to offer organ protection 5, 6. Sulfonylureas remain an option when cost is a major consideration or when other agents are contraindicated, but they are no longer preferred second-line agents after metformin 7.